Denovo Biopharma Buys Drug From Eli Lilly

San Diego-based biopharmaceuticals firm Denovo Biopharma said Tuesday that it has acquired a cancer drug from Eli Lilly and Company. According to Denovo, it acquired the late stage oncology drug enzastaurin from Eli Lilly, gaining all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information. Financial details of the buy were not disclosed.